|
|
Cytonome Awarded SBIR Phase II Grant from NIDDK
Watertown, MA, March 01, 2005 – Cytonome, Inc., developer of the clinical grade Gigasort™ optical cell sorter, today announced that it has been awarded a Phase II Small Business Innovative Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The grant was awarded to support Cytonome’s development of an ultra high throughput, high purity cell sorter for stem cell harvesting applications.
“There is considerable interest in using optical cell sorting for stem cell transplantation and other cell therapy applications. One of the major roadblocks in the successful application of transplant treatments is the difficulty in rapidly obtaining a sample of rare cells using clinical-grade optical sorting techniques.” said Dr. Manish Deshpande, Vice President of Engineering at Cytonome.
“The ultimate objective of our research is the development of an ultra high throughput high purity cell sorting technology, Gigasort, for stem cell and other cell therapy applications. The cell sorter contains a parallel array of microsorters that combine to produce throughput that is expected to be at least 10x that of current generation cell sorters in practice, using closed, sterile, disposable fluidics. We are extremely pleased that NIDDK recognizes the need for this technology and is supporting our efforts,” added John Gilbert Ph.D., Chairman and Chief Executive Officer of Cytonome.
About Cytonome
Cytonome, Inc. develops, manufactures and markets clinical grade optical cell sorting technology. Cytonome's Gigasort system is the only clinical-grade optical cell sorter using a sterile, disposable cartridge for precise and safe selection of discrete cell populations. Our revolutionary technologies are used to translate cellular therapies from laboratory to clinic.
For additional information on Cytonome, please visit the Company’s website at www.cytonome.com.
|
